Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia

Jaspal Kaeda, Frauke Ringel, Christian Oberender, Ken Mills, Concetta Quintarelli, Fabrizio Pane, Steffen Koschmieder, Robert Slany, Rolf Schwarzer, Giuseppe Saglio, Philipp Hemmati, Antje van Lessen, Leila Amini, Martin Greese, Elisabetta Vagge, Thomas Burmeister, Anna Serra, Anne Carson, Michaela Schwarz, Jörg WestermannFranziska Jundt, Bernd Dörken, Philipp le Coutre

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)


A better understanding of events triggering chronic myeloid leukemia progression are critical to optimised clinical management of chronic myeloid leukemia (CML). We sought to validate that increased Musashi 2 (MSI2), a post transcription regulator, expression is associated with progression and prognosis. Screening of 152 CML patients showed MSI2 was significantly decreased among CML patients in CP at diagnosis (p<0.0001), but found no significant difference between the normal control group and treated CML patients in CP. Moreover it was significantly increased (p<0.0001) in advance disease (AD) CML patients. Furthermore, our human hematopoietic cell line data imply MSI2 and BCR-ABL1 mRNA expression correlate. However, these data cast a doubt on earlier reports that MSI2 effects HES1 expression via NUMB-NOTCH signaling.
Original languageEnglish
Pages (from-to)2105-2113
JournalLeukemia & lymphoma
Issue number7
Early online date17 Jul 2015
Publication statusPublished - 2015


Dive into the research topics of 'Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia'. Together they form a unique fingerprint.

Cite this